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ood disorders are the most frequent psychiatric
comorbidity in patients with epilepsy.
1 For example,in a
population-based study carried out in Canada,Tellez-
Zenteno et al found a 17.4% lifetime prevalence of major
depressive disorders in these patients (95%CI:10.0-24.9)
compared with 10.7% (95%CI:10.2-11.2) in the general
population.
2 Furthermore,patients with epilepsy had a
24.4% (95%CI: 16.0-32.8) lifetime prevalence for any
type of mood disorder vs 13.2% (95%CI: 12.7-13.7)
among the general population.In addition,the lifetime
prevalence of suicidal ideation was twice as high in
patients with epilepsy (25%;95%CI:17.4-32.5) compared
with that of the general population (13.3%;95%CI 12.8-
13.8).Among the different types of epilepsy, temporal
lobe epilepsy (TLE) and frontal lobe epilepsy (FLE)
have been associated most frequently with the occur-
rence of mood disorders.
1The high association between
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Mood disorders are the most frequent psychiatric comorbidity in epilepsy, and in particular in temporal lobe epilepsy.
For a long time, depressive disorders were considered to be the expression of a reactive process to the obstacles of a
life with epilepsy. Data obtained in the last two decades, however, have demonstrated biochemical, neuropatholog-
ical, and neurophysiologic changes mediating the development of mood disorders, which in fact can be tested in ani-
mal models. Furthermore, there is also evidence that mood disorders and epilepsy have a complex relationship which
is bidirectional; that is, not only are patients with epilepsy at greater risk of developing depression, but patients with
depression have a higher risk of developing epilepsy. Such a relationship can only be explained by the existence of
common pathogenic mechanisms that are operant in both conditions. These include changes in neurotransmitters,
such as serotonin, norepinephrine, glutamate, and -aminobutyric acid. Such a bidirectional relationship also appears
to have important clinical consequences. Indeed, patients with a history of mood disorders are twice as likely to develop
pharmacoresistant epilepsy as those without such a history. These data are reviewed in this article.     
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:39-45.TLE and FLE on the one hand and mood disorders on
the other is not surprising,given the evidence that these
conditions may share common pathogenic mechanisms.
The purpose of this article is to review such evidence.
Animal models
How does epileptic activity facilitate the development
of symptoms of depression?
In a recent study, Mazarati et al investigated whether
chronic increase in seizure susceptibility induced by kin-
dling results in the development of behavior suggestive
of “symptoms of depression”in rats.
3To that end,3-week-
old Wistar rats underwent a rapid kindling with 84 sub-
convulsant electrical stimulations to the ventral hip-
pocampus every 5 minutes. Two to 4 weeks later, the
investigators subjected the rats to two tests,the forced
swim test (FST) and the test of taste preference for calo-
rie-free saccharin or sucrose solutions.These tests are
widely used in the investigation of the equivalent symp-
toms of depression in animal models.In the FST,the rat
is placed in a situation of despair, which allows for the
assessment of its ability to adopt active strategies in an
inescapable stressful situation. Failure to do so, as evi-
denced by increased immobility time during the FST,is
interpreted as being equivalent to a depression-like state.
The second test tries to replicate the loss of the animal’s
ability to experience pleasure.In rats,such symptoms can
be assessed by the loss of taste preference;although nor-
mal animals prefer sweetened to regular water,animals
with suspected depression do not exhibit such a prefer-
ence.
Mazarati et al found that kindled animals exhibited a sus-
tained increase in immobility time in the FST and the
loss of taste preference toward calorie-free saccharin,as
compared with controls.They concluded that that “the
neuronal plastic changes associated with the kindling
state are accompanied by the development of depressive
behavior.”
Neurotransmitter changes in animal models of
epilepsy: what do they have in common with mood 
disorders? 
The pathogenic role played by neurotransmitters such as
serotonin (5-HT),norepinephrine (NE),and dopamine
(DA) in the pathophysiology of mood disorders has been
recognized for four decades.
4 More recently,however,γ-
aminobutyric acid (GABA) and glutamate have been
identified as having a significant pathogenic role as well.
The pivotal pathogenic role of GABA and glutamate in
epilepsy has been demonstrated in multiple experimen-
tal studies with animals and humans.The role of 5-HT
and NE is less recognized,but well substantiated in ani-
mal and human studies. This section will focus on the
common pathogenic mechanisms mediated by NE and
5-HT in mood disorders and epilepsy.
The genetic epilepsy-prone rat (GEPR) with its two
strains (GEPR-3 and GEPR-9) provides an animal
model of both epilepsy and depression.
5 Both strains are
characterized by genetically determined predisposition
to sound-induced generalized tonic/clonic seizures
(GTCS) as well as marked kindling acceleration,with the
most rapid rate exhibited by GEPR-9.
5,6 In addition,
GEPRs display similar endocrine abnormalities to those
identified in patients with major depressive disorder,such
as increased corticosterone serum levels,deficient secre-
tion of growth hormone,and hypothyroidism.
5
Both strains of rats have innate noradrenergic and sero-
tonergic pre and postsynaptic transmission deficits.Of
note,GEPR-9 rats have a more pronounced NE trans-
mission deficit and,in turn,exhibit more severe seizures
than GEPR-3 rats.
5 Deficient arborization of neurons
arising from the locus coeruleus,coupled with excessive
presynaptic suppression of stimulated NE release in the
terminal fields and lack of postsynaptic compensatory
upregulation,mediate the noradrenergic deficiencies.
5-8
There is also evidence of deficits in serotonergic arboriza-
tion in the GEPR’s brain coupled with deficient postsy-
naptic serotonin1A (5-HT1A)receptor density in the hip-
pocampus.
5,9-11 Increments of either NE and/or 5-HT
transmission can prevent seizure occurrence,while reduc-
tion will have the opposite effect.
5 Thus, the selective
serotonin reuptake inhibitor (SSRI) sertraline resulted
in a dose-dependent seizure-frequency reduction in the
GEPR which correlates with the extracellular thalamic
serotonergic thalamic concentration.
10,11In addition,the
5-HT precursor 5-HTP has been shown to have anticon-
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Selected abbreviations and acronyms
5-HT serotonin
DA dopamine
GABA -aminobutyric acid
GEPR genetic epilepsy-prone rat
NE norepinephrine
TLE temporal lobe epilepsyvulsant effects in GEPRs when combined with a
monoamine-oxidase inhibitor (MAOI),while SSRIs and
MAOIs have been found to exert anticonvulsant effects
in genetically prone epilepsy mice and baboons,as well
as in non-genetically-prone cats,rabbits,and rhesus mon-
keys.
12-15
The antiepileptic effect mediated at the 5-HT1A recep-
tors has been related to a membrane hyperpolarizing
response associated with increased potassium conduc-
tance in hippocampal kindled seizures in cats, and in
intrahippocampal kainic acid-induced seizures in freely
moving rats.
16 In fact, antiepileptic drugs (AEDs) with
established psychotropic effects such as carbamazepine,
valproic acid,and lamotrigine have been found to cause
an increase in 5-HT.
17 Furthermore,the anticonvulsant
protection of carbamazepine can be blocked with 5-HT-
depleting drugs in GEPRs.
18
An anticonvulsant effect of serotonergic activity has been
reported in other animal models of epilepsy. Lopez
Meraz et al studied the impact of two 5-HT1A receptor
agonists, 8-OH-DPAT and indorenate, in three animal
models of epileptic seizures (clonic-tonic induced by
pentylenetetrazol (PTZ), status epilepticus of limbic
seizures induced by kainic acid (KA) and tonic-clonic
seizures induced by amygdala kindling) in Wistar rats.
19
8-OH-DPAT lowered the incidence of seizures and the
mortality induced by PTZ, increased the latency and
reduced the frequency of wet-dog shake and generalized
seizures induced by KA, and at high doses diminished
the occurrence and delayed the establishment of status
epilepticus.Indorenate increased the latency to the PTZ-
induced seizures and decreased the percentage of rats
that showed tonic extension and death,augmented the
latency to wet-dog shake and generalized seizures,and
diminished the number of generalized seizures.
Clinckers et al investigated the impact of oxcarbazepine
(OXC) infusion on the extracellular hippocampal con-
centration of 5-HT and DA in the focal pilocarpine
model for limbic seizures.
20When OXC was administered
together with verapamil or probenecid (so as to ensure
its passage through the blood-brain barrier),complete
seizure remission was obtained, associated with an
increase in 5-HT and DA extracellular concentrations.
21
In addition,it has been suggested that the anticonvulsant
effect of vagus nerve stimulation (VNS) in the rat could
be mediated by activation of the locus coeruleus.
22
Deletion of noradrenergic and serotonergic neurons in
the rat prevents or reduces significantly the anticonvul-
sant effect of VNS against electroshock or pentylenete-
trazol-induced seizures.
23 Of note,deletion of NE neurons
resulted in a significant immobility time in the FST.
Human studies
An abnormal serotonergic transmission has been found
in the brain of depressed patients through the measure-
ment of 5-HT1A receptors.
24-27 Using positron-emission
tomography (PET) imaging, a decrease in 
5-HT1A receptor binding has been also identified in
patients with TLE.
28-30 Deficits in 5-HT transmission in
human depression is thought to be partially related to a
paucity of serotonergic innervation of its terminal areas
suggested by a scarcity of 5-HT levels in brain tissue,
plasma, and platelets, and with a deficit in serotonin
transporter binding sites in postmortem human brain.
31-35
Serotonin stores and transporter protein are important
components of serotonin terminals,so that a combined
deficit is a plausible indicator of reduced axonal branch-
ing and synapse formation.
With respect to abnormal serotonergic activity in func-
tional neuroimaging studies of patients with primary
major depression,Sargent et al demonstrated reduced 5-
HT1A receptor binding potential of values in frontal,tem-
poral, and limbic cortex with PET studies using
[11C]WAY-100635 in both unmedicated and medicated
depressed patients compared with healthy volunteers.
24
Of note,binding potential values in medicated patients
were similar to those in unmedicated patients.Drevets et
al,using the same radioligand,reported a decreased bind-
ing potential of 5-HT1A receptors in mesial-temporal cor-
tex and in the raphe in 12 patients with familial recurrent
major depressive episodes,compared with controls.
25A
deficit in the density or affinity of postsynaptic 5-HT1A
receptors has been identified in the hippocampus and
amygdala of untreated depressed patients who commit-
ted suicide.
26 In addition, impaired serotonergic trans-
mission has been associated with defects in the dorsal
raphe nuclei of suicide victims with major depressive dis-
order,consisting of an excessive density of serotonergic
somatodendritic impulse-suppressing 5-HT1A autore-
ceptors.
27
Similar abnormalities in 5-HT1A receptor binding have
been identified in patients with TLE.For example,in a PET
study of patients with TLE using the 5-HT1A receptor
antagonist ([18F] trans-4-fluro-N-2-[4-(2-methoxyphenyl)
piperazin-1-yl]ethyl-N-(2-pyridyl) cyclohexanecarboxam-
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ral structures ipsilateral to the seizure focus,in patients with
and without hippocampal atrophy.
28 In addition, a 20%
binding reduction was found in the raphe and a 34% lower
binding in the ipsilateral thalamic region to the seizure
focus. In a separate PET study aimed at quantifying 5-
HT1A receptor binding in 14 patients with TLE,decreased
binding was identified in the epileptogenic hippocampus,
amygdala,anterior cingulate,and lateral temporal neocor-
tex ipsilateral to the seizure focus, as well as in the con-
tralateral hippocampi, but to a lesser degree, and in the
raphe nuclei.
29
Other investigators using the 5-HT1A tracer, 4,2-
(methoxyphenyl)-1-α[2-(N-2-pyridinyl)-p-fluorobenza-
mido]ethylpiperazine ([
18F]MPPF), found that the
decrease in binding of 5-HT1A was significantly greater
in the areas of seizure onset and propagation identified
with intracranial electrode recordings.As in the other
studies,reduction in 5-HT1A binding was present,even
when quantitative and qualitative MRI were normal.
30
Reduction in 5-HT1A receptor binding is not restricted
to patients with TLE. PET studies with the 5-HT1A
receptor antagonist carbonyl-carbon 11-WAY-100635
([11c]WAY-100635) found a decreased binding potential
in the dorsolateral prefrontal cortex,raphe nuclei,and
hippocampus of 11 patients with juvenile myoclonic
epilepsy compared with 11 controls.
36
In a recently published study, Hasler et al compared 
5-HT1A receptor binding between 37 TLE patients with
and without major depressive disorder (MDD) with inter-
ictal PET using the 5-HT1A antagonist [(18)F]FCWAY.
37
The MDD was diagnosed by clinical and structured psy-
chiatric interviews. They found that, in addition to a
decrease in 5-HT1A receptor binding in the epileptic focus,
patients with TLE and MDD exhibited a significantly
more pronounced reduction in 5-HT1A receptor binding,
extending into nonlesional limbic brain areas outside the
epileptic focus.The side of the ictal focus and the presence
of mesial temporal sclerosis were not associated with the
presence of comorbid depression.In a second study in 45
patients with TLE, Theodore et al demonstrated an
inverse correlation between increased severity of symp-
toms of depression identified on the Beck Depression
Inventory and 5-HT1A receptor binding at the ipsilateral
hippocampus to the seizure focus and to a lesser degree at
the contralateral hippocampus and midbrain raphe.
38
Likewise,Gilliam et al correlated the severity of symptoms
of depression using the BDI-II in 31 patients with TLE
with the magnitude of hippocampal abnormalities iden-
tified with 
1H magnetic resonance spectroscopic imaging
(
1H-MRSI) technique at 4.1 Tesla using creatine/N-acety-
laspartate ratio maps.
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Clinical implications
The existence of common pathogenic mechanisms
between mood disorders and epilepsy may explain the
higher incidence of mood disorders in patients with
epilepsy.In theory,however,patients with mood disorders
should be at greater risk of suffering from epilepsy fol-
lowing the development of the depressive disorder.Data
from three population-based studies appear to confirm this
hypothesis. Indeed, while, depression in patients with
epilepsy is typically conceptualized as a “complication”of
the seizure disorder,such a “unidirectional relationship”
between the two disorders was called into question in the
last 15 years,first in a Swedish population-based-case con-
trol study in which depression was found to be seven times
more common among patients with new-onset epilepsy,
preceding the seizure disorder,than among age- and sex-
matched controls.
40When analyses were restricted to cases
with a “localized-onset”seizure,depression was 17 times
more common among cases than among controls.Next,in
a population-based study that included all adults aged 55
years and older at the time of the onset of their epilepsy,
living in Olmstead County,Minnesota (USA),
41 the inves-
tigators found that a diagnosis of depression preceding the
time of their first seizure was 3.7 times more frequent
among cases than among controls after adjusting for med-
ical therapies for depression.As in the Swedish study,
40 this
increased risk was greater among cases with partial-onset
seizures. An interesting finding of this study was that,
among people with epileptic seizures,an episode of major
depression had taken place closer to the time of the first
seizure than for controls.Another population-based study
carried out in Iceland investigated the role of specific
symptoms of depression in predicting the development of
unprovoked seizures or epilepsy in 324 children and adults,
aged 10 years and older with a first unprovoked seizure or
newly diagnosed epilepsy and 647 controls.
42 Major depres-
sion was associated with a 1.7-fold increased risk for devel-
oping epilepsy while a history of attempted suicide was 5.1-
fold more common among cases than among controls.
Jones et al studied the cognitive and psychiatric profile
of 103 children aged 8 to 18 years,53 with recent onset
epilepsy (<1 year in duration) of idiopathic etiology and
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4250 healthy children matched for age.
43 Each child under-
went a structured psychiatric diagnostic interview to
characterize the spectrum of lifetime-to-date history of
comorbid psychiatric disorder.Compared with the con-
trol group,children with epilepsy exhibited an elevated
rate of lifetime-to-date Diagnostic and Statistical Manual
of Mental Disorders,4th edition (DSM-IV)
44Axis I dis-
orders,including significantly higher rates of depressive
disorders (22.6 vs 4%),anxiety disorders (35.8 vs 22%),
and attention-deficit-hyperactivity disorder (ADHD,26.4
vs 10%).Of note,45% of children with epilepsy exhib-
ited DSM-IVAxis I disorders before the first recognized
seizure.
Data from another study suggested that psychiatric
pathology could be a risk factor for the development of
unprovoked nonfebrile seizures and epilepsy in children.
For example, McAfee et al conducted a retrospective
cohort study in 133 440 pediatric patients (age 6 to 17
years) without history of seizures or prior use of anti-
convulsant medications.
45The data source for this study
was a research database containing pharmacy and med-
ical claims for members of a large US-based managed
care organization.The incidence rate of seizures among
children without psychiatric diagnoses was 149 per 100
000 person-years (95% CI 122-180), while that among
children with psychiatric diagnoses other than ADHD
was 513 per 100 000 person-years (95% CI 273-878).
The impact of a history of depression 
preceding the onset of epilepsy 
on the course of the seizure disorder
The existence of common pathogenic mechanisms
appears to have an impact on the response to treatment
of epileptic seizures. For example, in a study in 780
patients with newly diagnosed epilepsy that were fol-
lowed over a 20-year period, Hitiris et al found that
seizures had been controlled in 462 patients,while in 318
patients epilepsy remained refractory to AED therapy.
46
Univariate and multivariate logistic regression analyses
demonstrated that pharmacoresistance was associated
with prior or current psychiatric comorbidity,particularly
depression and intermittent recreational drug use.
The negative impact of psychiatric history on seizure con-
trol has not been restricted to pharmacotherapy,but has
been identified in studies that investigated postsurgical
seizure outcome following an anterotemporal lobectomy
(ATL).The first study by Anhoury et al reported that a
presurgical psychiatric history was associated with a
worse postsurgical seizure outcome following an ATL in
126 patients.
47 In a recent study, Kanner et al demon-
strated that a lifetime history of depression was a pre-
dictor of failure to reach a postsurgical seizure outcome
free of auras and disabling seizures following an ATL in
100 consecutive patients followed for a mean period of
8.3±3.3 years.
48 (Kanner et al,unpublished material).
Conclusion
The data presented in this article are clearly indicative of
a complex relationship between mood disorders and
epilepsy,which is based on the sharing of common path-
ogenic mechanisms.This review was restricted to the role
of NE and 5-HT.Yet, the potential pathogenic mecha-
nisms include DA, GABA, and glutamate, as well as
abnormalities of common neuroanatomical structures
that are part of the limbic circuit, including amygdala,
hippocampus, orbitofrontal and mesial frontal cortex,
nucleus accumbens, basal ganglia and thalamic nuclei,
and the raphe nuclei and locus coeruleus.
49The implica-
tions for neurologists are not merely theoretical,but bear
great significance with respect to the negative impact of
mood disorders on the response to pharmacologic and
surgical treatments of seizures. ❏
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Trastorno afectivo y epilepsia: 
una perspectiva neurobiológica de su 
relación
Los trastornos afectivos constituyen la comorbilidad
más frecuente en la epilepsia, particularmente en
la epilepsia del lóbulo temporal. Por largo tiempo
los trastornos depresivos fueron considerados
expresión de un proceso reactivo a los obstáculos
de una vida con epilepsia. Sin embargo, datos obte-
nidos en las últimas dos décadas han demostrado
cambios bioquímicos, neuropatológicos y neurofi-
siológicos que median el desarrollo de los trastor-
nos del ánimo, los que de hecho pueden ser pro-
bados en modelos animales. También existe
evidencia que los trastornos afectivos y la epilepsia
tienen una compleja relación que es bidireccional;
esto significa que no sólo los pacientes con epilep-
sia tienen mayor riesgo de desarrollar depresión,
sino que los pacientes con depresión tienen mayor
riesgo de desarrollar epilepsia. Tal relación sólo
puede ser explicada por la existencia de mecanis-
mos patogénicos comunes que operan en ambas
direcciones. Estos incluyen cambios en neurotrans-
misores como serotonina, noradrenalina, glutamato
y ácido gama-aminobutírico. Esta relación bidirec-
cional también parece tener importantes conse-
cuencias clínicas. De hecho, pacientes con historia
de trastornos afectivos duplican la probabilidad de
desarrollar epilepsia resistente a fármacos en rela-
ción con aquellos que no tienen ese antecedente.
Estos datos son revisados en este artículo. 
Troubles de l’humeur et épilepsie : 
perspective neurobiologique de leur 
interaction
Le trouble de l’humeur est la comorbidité la plus fré-
quente au cours de l’épilepsie, et en particulier de
l’épilepsie du lobe temporal. Les troubles dépressifs
de l’épileptique ont pendant longtemps été consi-
dérés comme l’expression d’une réaction aux obs-
tacles rencontrés au cours de la vie. Les données
obtenues ces 10 dernières années ont néanmoins mis
en évidence des changements biochimiques, neuro-
pathologiques et neurophysiologiques facilitant
l’émergence des troubles de l’humeur, et pouvant en
fait être testés sur des modèles animaux. De plus, il
existe également des arguments en faveur d’une
relation complexe, bidirectionnelle, entre les troubles
de l’humeur et l’épilepsie; non seulement les patients
épileptiques ont plus de risque de développer une
dépression, mais les patients dépressifs ont quant à
eux un risque plus élevé de développer une comitia-
lité. Une telle relation ne peut s’expliquer que par
l’existence de mécanismes pathogéniques communs
intervenant dans les deux affections. Des modifica-
tions au niveau des neurotransmetteurs, comme la
sérotonine, la norépinéphrine, le glutamate et
l’acide -aminobutyrique en font partie. Ces relations
bidirectionnelles entraînent des conséquences cli-
niques importantes. En effet, les patients ayant des
antécédents de troubles de l’humeur ont deux fois
plus de risque de développer une épilepsie pharma-
corésistante que ceux qui en sont indemnes. Ces don-
nées sont examinées dans notre article.
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